Abiopharma

🔍 LEWIS JOEL (Executive)

Company: GALECTIN THERAPEUTICS INC (GALT)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Sold 56,332 shares of Common Stock at $3.88 per share (Direct)
  Date: 2026-01-05 | Code: | shares_owned_after: 776,260.00 | Footnotes: F1, F3, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-05 | Code: H | nature_of_ownership: as USTA custodian for a minor child | shares_owned_after: 2,000.00 | Footnotes: F4

Footnotes:

• F1: Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units ("DSUs") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs from the amended agreement shall be settled in shares of Common Stock as follows: (i) fifty percent shall be settled on March 1, 2025 and (ii) fifty percent shall be settled on January 5, 2026.
• F2: Represents shares underlying DSUs and Common Stock.
• F3: Represents shares withheld from issuance to Mr. Lewis (but not sold) for federal and state withholding taxes on income.
• F4: These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.